Cell Pathways preclinical data

Published animal results show that FGN-1 gives dose-dependent reductions in tumor incidence, tumor spread, and tumor

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE